RANI
Rani TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Rani now has a cleaner balance sheet, a Phase 1 obesity asset already started, and monetizable collaboration economics through Chugai that could validate the RaniPill platform beyond pure concept-stage enthusiasm [#8-K-2026-03-26][#10-K-2026-03-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash runway shortens if program spending ramps faster than expected or milestone receipts slip.
Momentum
85
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.60 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.25
Why
Momentum85 · Δ7d -
Value41 · Δ7d +0.1
Sentiment55 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
55
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 84.6 / Value 41.1 / Sentiment 55.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$110.96M
Beta
0.44
Shares Out
121.52M
P/E (TTM) · Derived
-0.9
P/S (TTM)
137.72
P/FCF (TTM) · Derived
-1.23
Rev YoY
-
EPS YoY
+50.5%
Gross Margin
-
Op Margin
-3727.8%
Net Debt
-$3.03M
Current Ratio
0.26
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology